Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Biomarkers of cholestasis

Full text
Pieters, Alanah [1] ; Gijbels, Eva [1] ; Cogliati, Bruno [2] ; Annaert, Pieter [3] ; Devisscher, Lindsey [4] ; Vinken, Mathieu [1]
Total Authors: 6
[1] Vrije Univ Brussel, Dept In Vitro Toxicol & Dermatocosmetol, Laarbeeklaan 103, B-1090 Brussels - Belgium
[2] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Av Prof Dr Orlando Marques Paiva 87, BR-05508270 Cidade Univ, SP - Brazil
[3] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Drug Delivery & Disposit, ON 2 Herestr 49, Box 921, B-3000 Leuven - Belgium
[4] Univ Ghent, Fac Med & Hlth Sci, Gut Liver Immunopharmacol Unit, Basic & Appl Med Sci, C Heymanslaan 10, B-9000 Ghent - Belgium
Total Affiliations: 4
Document type: Review article
Source: BIOMARKERS IN MEDICINE; v. 15, n. 6 MAR 2021.
Web of Science Citations: 0

Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The `omics' era, however, has resulted in a plethora of cholestatic indicators, yet a single, clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks. (AU)

FAPESP's process: 18/10953-9 - Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?
Grantee:Bruno Cogliati
Support type: Regular Research Grants